Current role
Xiaolin Wang Sc.D
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Xiaolin Wang Sc.D
The proxy statement of Revolution Medicines, Inc. reports total compensation of $1,791,780 for Xiaolin Wang Sc.D in fiscal 2022, including a base salary of $400,000. Disclosed compensation is on record for 2 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Revolution Medicines, Inc. (RVMD)
Proxy statement
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Revolution Medicines, Inc.
Other people whose current roles at this company are on record from its filings.
- Mark Goldsmith CEO, Board Member
- Jack Anders CFO
- Margaret Horn COO
- Jeffrey Cislini General Counsel
- Alexis Borisy Board Member
- Elizabeth McKee Anderson Board Member
- Eric Schmidt Board Member
- Flavia Borellini Board Member
- Frank K. Clyburn Board Member
- Frank K. Clyburn, Jr. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Revolution Medicines, Inc. (RVMD) | Executive Vice President and Clinical Development | $400,000 | $1,791,780 |
| 2021 | Revolution Medicines, Inc. (RVMD) | Executive Vice President and Clinical Development | $377,833 | $2,167,809 |
Recent activity
No call appearances or filed executive changes recorded yet.